HLS Therapeutics Inc has seen a notable uptick in its stock price, closing up 3.52% in the last trading session.
On the TSX, HLS Therapeutics Inc (HLS.TO) experienced a positive trading day, with shares rising to CA$4.41. This increase comes amid ongoing developments in the company's product portfolio and financial performance.
Investor takeaway: Investors should keep an eye on HLS Therapeutics as it continues to expand its cardiovascular offerings and improve its financial health, which may drive further stock performance.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
HLS Therapeutics Inc
HLS.TO
HLS.TO
HLS Therapeutics Inc
WealthAwesomeMarket cap
$128.54M
52W high
$5.76
52W low
$4.00
1W change
-2.84%
Beta
0.86
Analyst Price Targets
Based on analyst covering HLS
Wall Street analysts forecast HLS stock price to rise 76.5% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$7.26
+76.5% Upside
Current Price
C$4.11
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on HLS's historical volatility
30-Day Vol
29.9%
Annualized
90-Day Vol
22.6%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$3.44
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$3.87 | C$3.49 – C$4.29 |
| 60 trading days | C$3.65 | C$3.15 – C$4.22 |
| 90 trading days | C$3.44 | C$2.88 – C$4.11 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
HLS Therapeutics Inc sees a 3.52% increase in stock price.
With a market cap of CA$137.9 million, HLS Therapeutics is navigating a competitive landscape while working to improve its financial metrics.
Bull case
The recent launch of NILEMDO™ and the growth in Vascepa net sales suggest that HLS Therapeutics is making strides in expanding its market presence. This could lead to steady revenue growth as they enhance their offerings in the cardiovascular space.
Bear case
Despite the positive movement, HLS Therapeutics still faces challenges. They have a negative profit margin and depend on a limited product range, which could affect their long-term profitability.
Recent Financial Performance
HLS Therapeutics recently reported a revenue increase of 2% year-over-year for Q1 2026, reaching CA$12.9 million. Notably, Vascepa net sales grew by 15%, indicating strong demand for its cardiovascular products. This financial uptick is likely contributing to the stock's positive movement.
Product Portfolio Expansion
The launch of NILEMDO™ in April 2026 marks a significant addition to HLS's cardiovascular portfolio. This expansion is expected to enhance the company's market position and could attract more investors looking for growth opportunities.
Debt Reduction Efforts
HLS Therapeutics has made strides in reducing its net debt, which fell to CA$31.9 million, a 32% decrease from the previous year. This financial maneuver not only improves the company's balance sheet but also positions it for future growth, potentially reassuring investors about its financial stability.
Advertisement
